The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Latest updates in CAR-T therapy for follicular lymphoma
Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an overview of recent advances in CAR-T therapy for follicular lymphoma (FL). Axicabtagene ciloleucel (axi-cel) was the first CAR-T therapy to be approved in FL. The promising results of the ZUMA-5 (NCT03105336) and ELARA (NCT03568461) studies are expected to lead to the approval of tisagenlecleucel (tisa-cel) in relapsed/refractory (R/R) FL. Further longitudinal data is required to better understand the impact of CAR-T therapy in patients with FL, as well as to determine which patients are most likely to benefit from this immunotherapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Disclosures
Consultant and/or advisory board member for AbbVie, Bayer, BeiGene, BMS, Janssen, Karyopharm, Kite Pharma/Gilead, Novartis, Nurix, and Takeda. Speaker for Kite Pharma/Gilead and he has received honoraria from Novartis. Research support from BMS, Calibr, CRISPR Therapeutics, Fate Therapeutics, Kite Pharma/Gilead, MorphoSys, Novartis, Tessa Therapeutics, and Xencor.
